Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?
Ozkan GungorMustafa SevincSena UluIsmail KocyigitPublished in: International urology and nephrology (2022)
Cardiovascular disease (CVD) incidence is high in patients with chronic kidney disease (CKD) and is the most frequent cause of mortality in this population. Advanced age, hypertension, uremic toxins, endothelial dysfunction, atherosclerosis, hyperhomocysteinemia, oxidative stress, and inflammation are among the leading causes of increased CVD in advanced stages of CKD. Although defined as a decrease in muscle strength associated with aging, sarcopenia is also prevalent in CKD patients. Sarcopenia causes physical disability, low quality of life, and mortality. Regular exercise and nutritional supplementation may slow the progression of sarcopenia. Recent studies have shown that sarcopenia increases the risk of CVD and mortality in people with or without kidney disease. This review discusses the relationship between sarcopenia and CVD in light of the current literature.
Keyphrases
- cardiovascular disease
- skeletal muscle
- chronic kidney disease
- end stage renal disease
- oxidative stress
- cardiovascular events
- community dwelling
- risk factors
- physical activity
- blood pressure
- systematic review
- ejection fraction
- mental health
- dna damage
- peritoneal dialysis
- cardiovascular risk factors
- signaling pathway
- endoplasmic reticulum stress
- arterial hypertension